A Phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer. A multi-centre Phase II trial to determine the activity and safety of durvalumab in advanced endometrial cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Jun 2023 Results assessing impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
01 Feb 2022 Status changed from active, no longer recruiting to completed.
11 Nov 2021 Planned End Date changed from 16 Aug 2020 to 1 Jun 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com